Under a proposal currently before policymakers, Medicare rebates would be broadened to cover more than 30 procedures tied to gender-affirming treatment — costs that at present fall largely on patients themselves. Prices attached to these procedures vary widely, with vaginoplasty carrying a price tag that can reach $60,000 and facial feminisation surgery running as high as $80,000.
A formal request lodged by the Australian Society of Plastic Surgeons seeks to add Medicare Benefits Schedule listings for consultations and surgical procedures available to adults whose experienced gender does not align with the sex recorded at their birth. A funding recommendation for the proposal now rests with the Medical Services Advisory Committee (MSAC), the body tasked with advising Australia's federal government on which new medical services warrant public financing.
Among the Medicare item numbers the ASPS is seeking to have created are those covering pre- and post-operative consultations, along with a range of procedures — chest masculinisation, breast augmentation, hysterectomy, removal of ovaries or testes, vaginoplasty, phalloplasty, metoidioplasty, and facial feminisation surgery.
Obtaining financial support for such procedures remains out of reach for many. Where funding gaps exist, certain patients draw on Medicare items not originally intended for this category of treatment, while others either absorb the costs privately or seek care abroad.
The Australian Society of Plastic Surgeons contends that the proposed amendments would establish a more defined and uniform pathway for adults seeking this category of procedure and associated care. The submission describes the package of changes to the Medicare Benefits Schedule as aimed at building a multidisciplinary model of care that supports patients at every stage of their treatment journey, not only around the time of any operation.
According to the filing, more than 128,000 people in Australia may identify as transgender and fall within the population considered eligible for the relevant medical procedures. Projections put the number of people who would use the proposed services at roughly 47,087 during the first full year of operation, with the associated public expenditure potentially running into the millions.
Those who back the procedures point to evidence that they can improve both wellbeing and mental health outcomes for patients. According to ASPS documentation, transgender and gender-diverse individuals face elevated rates of depression, anxiety, and suicidal ideation, with a portion of those affected pursuing medical or surgical options as components of their overall treatment.
A broader examination of the clinical evidence has been called for by MSAC, which determined that the materials originally put forward fell short of covering all relevant information under its established guidelines. Regulators determined that the proposed procedures needed to undergo a fuller evaluation of both their outcomes and patient safety before the application could advance.
Variations in how patients gain access to surgical treatment emerged as a prominent finding across different countries in the review. The document noted that psychological evaluation and an official diagnosis — whether of gender dysphoria or gender incongruence — stand as prerequisites under the laws of numerous nations. Hormone therapy is typically required for a period of time before individuals can proceed to surgical intervention.
Two distinct phases structure how MSAC is approaching the application — the first phase weighs clinical evidence and safety, while the second turns to the economic case for public funding and its financial consequences. A vote on the matter is expected to take place before the end of the year.
